HFpEF的新面孔:全身性炎症

Folia Cardiologica Pub Date : 2023-08-21 DOI:10.5603/fc.96384

Małgorzata Lelonek

{"title":"HFpEF的新面孔:全身性炎症","authors":"Małgorzata Lelonek","doi":"10.5603/fc.96384","DOIUrl":null,"url":null,"abstract":"Systemic inflammation is proposed as background of development and progres of heart failure, especially in heart failure with preserved ejection fraction (HFpEF). High-sensitivity C-reactive protein seems to be an optimal biomarker of systemic inflammation. Knowledge of systemic inflammation is important for new therapeutic fields in HFpEF with potential in inhibition of IL-1β, IL-6 or galectin-3.","PeriodicalId":12308,"journal":{"name":"Folia Cardiologica","volume":"34 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The new face of HFpEF: systemic inflammation\",\"authors\":\"Małgorzata Lelonek\",\"doi\":\"10.5603/fc.96384\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Systemic inflammation is proposed as background of development and progres of heart failure, especially in heart failure with preserved ejection fraction (HFpEF). High-sensitivity C-reactive protein seems to be an optimal biomarker of systemic inflammation. Knowledge of systemic inflammation is important for new therapeutic fields in HFpEF with potential in inhibition of IL-1β, IL-6 or galectin-3.\",\"PeriodicalId\":12308,\"journal\":{\"name\":\"Folia Cardiologica\",\"volume\":\"34 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-08-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Folia Cardiologica\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5603/fc.96384\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Folia Cardiologica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5603/fc.96384","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

全身炎症被认为是心衰发生和进展的背景，特别是在保留射血分数的心力衰竭(HFpEF)中。高灵敏度c反应蛋白似乎是全身性炎症的最佳生物标志物。了解全身性炎症对抑制IL-1β、IL-6或半乳糖凝集素-3的HFpEF的新治疗领域很重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The new face of HFpEF: systemic inflammation

Systemic inflammation is proposed as background of development and progres of heart failure, especially in heart failure with preserved ejection fraction (HFpEF). High-sensitivity C-reactive protein seems to be an optimal biomarker of systemic inflammation. Knowledge of systemic inflammation is important for new therapeutic fields in HFpEF with potential in inhibition of IL-1β, IL-6 or galectin-3.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Folia Cardiologica

自引率

0.00%

发文量

审稿时长

10 weeks